NCT01673282

Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy

A Non-interventional, Observational Study Evaluating Changes in Drug Load and Seizure Frequency Using Vimpat (Lacosamide) in Daily Clinical Practice in Combination Therapy With Sodium Channel Blocking Anti-epileptic Drugs (AEDs) or Non Sodium Channel Blocking AEDs

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 315 (actual)
• Sponsor: UCB Pharma GmbH · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This observational study aims to investigate how VIMPAT® is used as adjunctive therapy in clinical practice and will also evaluate the subsequent change in the drug load of patients after addition of VIMPAT® to their treatment regimen.

Conditions

• Focal Epilepsy With and Without Secondary Generalization

Interventions

Type	Name	Description
DRUG	Lacosamide	Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).

Timeline

• Start date: 2012-07-01
• Primary completion: 2015-07-01
• Completion: 2015-07-01
• First posted: 2012-08-27
• Last updated: 2016-11-15
• Results posted: 2016-11-15

Locations

42 sites across 2 countries: Austria, Germany